The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Salugina S.O.

V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia ,

Gorodetsky V.R.

V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia

Fedorov E.S.

V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia ,

Lopatina N.E.

FGBU "NII revmatologii im. V.A. Nasonovoĭ" RAMN, Moskva

Evsikova М.D.

V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia

Schnitzler syndrome: A review of literature, the authors’ observation, and experience with the interleukin-1 inhibitor canakinumab

Authors:

Salugina S.O., Gorodetsky V.R., Fedorov E.S., Lopatina N.E., Evsikova М.D.

More about the authors

Journal: Therapeutic Archive. 2017;89(11): 111‑115

DOI: 10.17116/terarkh20178911111-115

Read: 3250 times

Download PDF (RU)
Contact the author
Table of contents

SCHNITZLER SYNDROME: A REVIEW OF LITERATURE, THE AUTHORS’ OBSERVATION, AND EXPERIENCE WITH THE INTERLEUKIN-1 INHIBITOR CANAKINUMAB
SCHNITZLER SYNDROME: A REVIEW OF LITERATURE, THE AUTHORS’ OBSERVATION, AND EXPERIENCE WITH THE INTERLEUKIN-1 INHIBITOR CANAKINUMAB

To cite this article:

Salugina SO, Gorodetsky VR, Fedorov ES, Lopatina NE, Evsikova МD. Schnitzler syndrome: A review of literature, the authors’ observation, and experience with the interleukin-1 inhibitor canakinumab. Therapeutic Archive. 2017;89(11):111‑115. (In Russ.)
https://doi.org/10.17116/terarkh20178911111-115

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Unre­solved problem: Chemotherapy-Induced Peri­pheral Neuropathy. P.A. Herzen Journal of Onco­logy. 2024;(5):76-81
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90
The asso­ciation of NOS1AP gene poly­morphisms with the dura­tion of the QT inte­rval in patients with schi­zophrenia receiving anti­psychotic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):98-104
Characteristics, treatment features and in-hospital mortality of patients with myocardial infa­rction over 75 years old in Russia acco­rding to the REGION-IM regi­stry. Russian Cardiology Bulletin. 2025;(1):22-38
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Chro­nic obstructive pulmonary disease (COPD 2024). Clinical guidelines (short version). Journal of Respiratory Medi­cine. 2025;(2):5-16
Community-acquired pneumonia in adults. Clinical guidelines 2024 (short version). Journal of Respiratory Medi­cine. 2025;(3):6-18
Abstract:

The paper reviews the publications dealing with Schnitzler syndrome, a rare autoinflammatory disease, and describes the authors’ own clinical observation. It describes the first Russian experience in successfully using the interleukin-1 inhibitor canakinumab to treat this disease.

Keywords:

autoinflammatory diseases
Schnitzler syndrome
therapy
IL-1 inhibitors
canakinumab

Authors:

Salugina S.O.

V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia ,

Gorodetsky V.R.

V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia

Fedorov E.S.

V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia ,

Lopatina N.E.

FGBU "NII revmatologii im. V.A. Nasonovoĭ" RAMN, Moskva

Evsikova М.D.

V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia

Close metadata

References:

  1. Simon A, Asli B, Braun-Falco M et al. Schnitzler Syndrome: diagnosis, treatment, and follow-up. Allergy. 2013;68:562-568.
  2. Lipsker D, Veran Y, Grunenberger F et al. The Schnitzler Syndrome Four new cases and review of the literature. Medicine. 2001;80:37-44.
  3. De Koning HD., Bodar EJ., van der Meer JW. Schnitzler Syndrome Study Group. Schnitzler Syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum. 2007;37:137-148.
  4. Schnitzler L, Schubert B,Boasson M et al. Urticaire chronique, lesions osseuses, macroglobulinemie IgM maladie de Waldenstrom. Bull Soc Franc Derm Syph. 1974;81:363.
  5. Lipsker D. The Schnitzler syndrome Orphanet Journal of Rare Diseases. 2010;5:38-45.
  6. Saurat JH, Schifferly J, Steiger G et al. Anti-interleukin-1 alpha autoantibodies in humans: characterization, isotype distribution and receptor-binding inhibition-higher frequency in Schnitzler’s syndrome (urticaria and macroglobulinemia). J Allergy Clin Immunol. 1991;88:244-56.
  7. Sokumbi O, Drage LA, Peters MS. Clinical and histopathologic review of Schnitzler syndrome: the Mayo Clinic experience (1972-2011). J Am Acad Dermatol. 2012;67:1289-1295.
  8. Tinazzi E, Puccetti A, Patuzzo G et al. Schnitzler syndrome, an autoimmune-autoinflammatory syndrome: report of two new cases and review of the literature. Autoimmun Rev. 2011;10:404-409.
  9. Neel A, Henry B, Barbarot S et al. Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler syndrome: a french multicenter study Autoimmunity. Reviews. 2014;13:1035-1041.
  10. Eiling E, Moller M, Kreiselmaier I et al. Schnitzler syndrome: treatment failure to rituximab but response to anakinra. J Am Acad Dermatol. 2007;57:361-364.
  11. Zuberbier T, Maurer M. Urticarial Vasculitis and Schnitzler Syndrome. Immunol Allergy Clin N Am. 2014; 34:141-147.
  12. De Castro FR, Masouye I, Winkelmann RK, Saurat JH. Urticarial pathology in Schnitzler’s (hyper-IgM) syndrome. Dermatology. 1996;193:94-99.
  13. Gattorno M. Kriopirin - assotsiirovannyi periodicheskii sindrom (reprint). Voprosy sovremennoi pediatrii. 2013;12 (1):57-62. https://doi.org/10.15690/vsp.v14i3.1372
  14. Caso F, Rigante D, Vitale A et al. Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. International Journal of Rheumatology. 2013;Article ID513782,15pages. https://doi.org/10.1155/2013/513782
  15. Jain T, Offord CP, Kyle RA, Dingli D. Schnitzler syndrome: an under-diagnosed clinical entity. Haematol. 2013;98(10): 1581-1585.
  16. Claes K, Bammens B, Delforge M et al. Another devastating complication of the Schnitzler syndrome: AA amyloidosis. Br J Dermatol. 2008;158:182-184.
  17. Dalle S, Balme B, Sebban C et al. Schnitzler syndrome associated with systemic marginal zone B-cell lymphoma. Br J Dermatol. 2006;155:827-829.
  18. Martinez-Taboada VM, Fontalba A, Blanco R, Fernandez-Luna JL. Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al. Arthritis Rheum. 2005;52:2226-2227.
  19. Gran JT, Midtvedt Q,Haug S, Aukrust P. Treatment of Schnitzler syndrome with anakinra: report of three cases and review of the literature. Scand J Rheumatol. 2011;40:74-79.
  20. Asli B, Bievenu B, Cardoliani F et al. Chronic Urticaria and Monoclonal IgM gammopathy (Schnitzler syndrome). Report of 11 cases treated with Pefloxacin. Arch Dermatol. 2007;143:1046-1050.
  21. Billey T, Beldjerd M, Popa L, Lassoued S. Schnitzler syndrome: a dramatic improvement with anakinra. Presse Med. 2010;39: 1338-1339.
  22. Krause K, Feist E, Fiene M, Kallinich T, Maurer M. Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome. J Allergy Clin Immunol. 2012;129:848-850.
  23. Krause K, Weller K, Stefaniak R, Wittkowski H, Altrichter S, Siebenhaar F et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome:an open-label study. Allergy. 2012;67:943-950.
  24. De Koning HD, Schalkwijk J, van der Meer JW, Simon A. Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome. J Allergy Clin Immunol. 2011;128: 1352-1354.
  25. Vanderschueren S, Knockaert D. Canakinumab in Schnitzler syndrome. Semin Arthritis Rheum. 2013;42:413-416.
  26. Krause K, Tsianakas A,Wagner N et al. Efficacy and safety of canakinubab in Schnitzler syndrome: a multicenter randomized placebo-controlled study. 2016; J Allergy Clin Immunol. 2016 Sep 19. pii: S0091-6749(16)30968-X. https://doi.org/10.1016/j.jaci.2016.07.041
  27. Federici S, Martini A, Gattorno M. The central role of anti-IL-1 blockade in the treatment of monogenic and multi-factorial autoinflammatory diseases. Frontiers un Immunology. 2013;4:351.
  28. Masters SL, Simon A, Aksetijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Ann Rev Immunol. 2009;27:621-668.
  29. Eiling E, Schroder JO, Gross WL et al. The Schnitzler syndrome: chronic urticaria and monoclonal gammopathy — an autoinflammatory syndrome? J Dtsch Dermatol Ges. 2008;6:626-631.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.